ZA200904331B - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents
Multivalent pneumococcal polysaccharide-protein conjugate compositionInfo
- Publication number
- ZA200904331B ZA200904331B ZA200904331A ZA200904331A ZA200904331B ZA 200904331 B ZA200904331 B ZA 200904331B ZA 200904331 A ZA200904331 A ZA 200904331A ZA 200904331 A ZA200904331 A ZA 200904331A ZA 200904331 B ZA200904331 B ZA 200904331B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein conjugate
- conjugate composition
- pneumococcal polysaccharide
- multivalent pneumococcal
- multivalent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/644,095 US7955605B2 (en) | 2005-04-08 | 2006-12-22 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200904331B true ZA200904331B (en) | 2010-03-31 |
Family
ID=39410470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200904331A ZA200904331B (en) | 2006-12-22 | 2009-06-19 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7955605B2 (pt) |
| EP (1) | EP2099494A2 (pt) |
| JP (1) | JP2010513559A (pt) |
| KR (1) | KR20090094163A (pt) |
| CN (1) | CN101600459A (pt) |
| AU (1) | AU2007337101A1 (pt) |
| BR (1) | BRPI0720738A2 (pt) |
| CA (1) | CA2673543A1 (pt) |
| CL (1) | CL2007003780A1 (pt) |
| MX (1) | MX2009006547A (pt) |
| RU (1) | RU2009123024A (pt) |
| WO (1) | WO2008079732A2 (pt) |
| ZA (1) | ZA200904331B (pt) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7955605B2 (en) * | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP3311836A1 (en) | 2005-04-08 | 2018-04-25 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20240408221A1 (en) * | 2005-04-08 | 2024-12-12 | Wyeth Llc | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| KR101515078B1 (ko) | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| ES2749952T3 (es) | 2008-12-18 | 2020-03-24 | Wyeth Llc | Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono |
| BRPI0922981A8 (pt) | 2008-12-18 | 2019-11-26 | Wyeth Llc | método para o controle do peso molecular polissacarídeo para o sorotipo 19a de streptococcus pneumoniae |
| EP2411048B1 (en) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
| EP3017826A1 (en) | 2009-03-24 | 2016-05-11 | Novartis AG | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| US20120052088A1 (en) | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| WO2011036560A2 (en) * | 2009-09-23 | 2011-03-31 | Novartis Ag | Glycoconjugate compositions and methods for treatment of hiv |
| GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| AU2012101554B4 (en) * | 2010-03-09 | 2013-05-09 | Glaxosmithkline Biologicals S.A. | Conjugation process of bacterial polysaccharides to carrier proteins |
| PL2575870T3 (pl) | 2010-06-04 | 2017-05-31 | Wyeth Llc | Preparaty szczepionek |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| JP2015505309A (ja) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ |
| EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン |
| US20150320852A1 (en) | 2012-12-18 | 2015-11-12 | Glaxosmithkline Biologicals Sa | Conjugates for protecting against diphtheria and/or tetanus |
| JP6502262B2 (ja) | 2012-12-20 | 2019-04-17 | ファイザー・インク | 糖複合化方法 |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2015017823A1 (en) * | 2013-08-02 | 2015-02-05 | The Uab Research Foundation | Tetravalent pneumococcal serogroup 6z |
| EP3511161A1 (en) | 2013-08-26 | 2019-07-17 | Corning Incorporated | Laminate structure |
| CN110859957B (zh) | 2014-01-21 | 2024-04-12 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| PL3096786T3 (pl) | 2014-01-21 | 2021-11-08 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
| HUE062499T2 (hu) | 2015-01-15 | 2023-11-28 | Pfizer | Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények |
| MY182282A (en) | 2015-05-04 | 2021-01-18 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US11147863B2 (en) | 2015-06-23 | 2021-10-19 | Biological E Limited | Multivalent pneumococcal conjugate vaccine |
| KR102225282B1 (ko) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| CA3031799A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| NZ752348A (en) | 2016-09-30 | 2022-11-25 | Biological E Ltd | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| EP4656208A3 (en) | 2017-01-31 | 2026-03-04 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| CN110225757A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法 |
| CA3052621A1 (en) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| MX2019009869A (es) | 2017-02-24 | 2019-10-02 | Merck Sharp & Dohme | Formulaciones de vacunas de conjugado de neumococos. |
| JP7680185B2 (ja) * | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強 |
| WO2018227177A1 (en) | 2017-06-10 | 2018-12-13 | Inventprise, Llc | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| WO2019050814A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| MX394767B (es) | 2017-09-07 | 2025-03-24 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. |
| MX394768B (es) | 2017-09-07 | 2025-03-21 | Merck Sharp & Dohme Llc | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina. |
| CN111093650B (zh) | 2017-09-07 | 2024-03-01 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
| WO2019070994A1 (en) | 2017-10-04 | 2019-04-11 | Liffey Biotech Limited | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE |
| KR20200077538A (ko) * | 2017-10-25 | 2020-06-30 | 머크 샤프 앤드 돔 코포레이션 | 아주반트 첨가된 백신 |
| ES3058336T3 (es) | 2017-12-06 | 2026-03-10 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos |
| BR112020014978A2 (pt) | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| EP3749357A4 (en) | 2018-02-05 | 2022-04-20 | Sanofi Pasteur, Inc. | POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION |
| US11951162B2 (en) * | 2018-04-18 | 2024-04-09 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof |
| EP3787673A4 (en) | 2018-04-30 | 2022-04-27 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| EP3788143B1 (en) | 2018-04-30 | 2023-06-28 | Merck Sharp & Dohme LLC | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
| US12144855B2 (en) | 2018-04-30 | 2024-11-19 | Merck Sharp & Dohme Llc | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| DK3817775T3 (da) | 2018-07-04 | 2024-09-16 | Vaxcyte Inc | Forbedringer i immunogene konjugater |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| CR20210333A (es) | 2018-12-19 | 2021-08-18 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso |
| WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| KR102754880B1 (ko) * | 2019-05-28 | 2025-01-13 | 에스케이바이오사이언스(주) | 스트렙토코커스 뉴모니애 혈청형 23f의 면역원성 접합체 제조방법 |
| PH12022550110A1 (en) | 2019-07-31 | 2022-12-12 | Sk Bioscience Co Ltd | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US20230000966A1 (en) | 2019-11-01 | 2023-01-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| BR112022014555A2 (pt) | 2020-02-23 | 2022-09-20 | Pfizer | Composições de escherichia coli e métodos das mesmas. |
| US12497640B2 (en) * | 2020-05-14 | 2025-12-16 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| KR20230056727A (ko) | 2020-08-26 | 2023-04-27 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| PE20231934A1 (es) | 2020-10-27 | 2023-12-01 | Pfizer | Composiciones de escherichia coli y metodos de las mismas |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| JP7804673B2 (ja) | 2020-11-10 | 2026-01-22 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| JP2024517780A (ja) | 2021-05-03 | 2024-04-23 | ファイザー・インク | 細菌およびベータコロナウイルス感染症に対するワクチン接種 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| JP2024521847A (ja) | 2021-05-28 | 2024-06-04 | ファイザー・インク | コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用 |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| CA3247998A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses |
| GB2614916A (en) * | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
| CA3256617A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2023403045A1 (en) | 2022-12-01 | 2025-06-12 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20252774A1 (es) | 2023-03-30 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| AU2024255922A1 (en) | 2023-04-14 | 2025-10-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20260015203A (ko) | 2023-05-19 | 2026-02-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025174398A1 (en) | 2024-02-14 | 2025-08-21 | Merck Sharp & Dohme Llc | 26-valent pneumococcal conjugate vaccines and methods of use thereof |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097666A (en) * | 1976-04-29 | 1978-06-27 | The Institute Of Paper Chemistry | Solvent system for polysaccharides |
| US5097020A (en) | 1983-07-05 | 1992-03-17 | The University Of Rochester | Immunogenic conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| US6709658B1 (en) * | 1998-02-12 | 2004-03-23 | Wyeth Holdings Corporation | Pneumococcal vaccines formulated with interleukin-12 |
| IL137809A0 (en) * | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| EP1115875A1 (en) | 1998-09-24 | 2001-07-18 | Regents Of The University Of Minnesota | Human complement c3-degrading polypeptide from streptococcus pneumoniae |
| EP1035137A1 (en) | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
| ATE459373T1 (de) | 1999-03-19 | 2010-03-15 | Glaxosmithkline Biolog Sa | Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae |
| CZ20024224A3 (cs) * | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| ATE267767T1 (de) | 2000-12-13 | 2004-06-15 | Sca Hygiene Prod Zeist Bv | Rückgewinnungsprozess für gebrauchtes periodat |
| GB0130215D0 (en) | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2003094961A1 (en) | 2002-05-09 | 2003-11-20 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
| WO2004011027A1 (en) | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Chimeric multivalent polysaccharide conjugate vaccines |
| WO2004026024A2 (en) * | 2002-09-20 | 2004-04-01 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine compositions and adjuvant |
| FR2850106B1 (fr) | 2003-01-17 | 2005-02-25 | Aventis Pasteur | Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5 |
| EP1651262A2 (en) * | 2003-08-06 | 2006-05-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Process for preparing polysaccharide-protein conjugate vaccines |
| DE602004025951D1 (de) | 2003-09-11 | 2010-04-22 | Staat Der Nederlanden Vert Doo | Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat-impfstoffen |
| FR2857364B1 (fr) | 2003-12-08 | 2005-09-23 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| KR101157694B1 (ko) | 2003-12-17 | 2012-06-20 | 와이어쓰 엘엘씨 | 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP3311836A1 (en) | 2005-04-08 | 2018-04-25 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| PE20110072A1 (es) * | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| KR101515078B1 (ko) | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| FR2908784B1 (fr) | 2006-11-17 | 2012-12-14 | Oreal | Utilisation cosmetique d'une proteine de la famille des ribonucleases |
-
2006
- 2006-12-22 US US11/644,095 patent/US7955605B2/en not_active Expired - Lifetime
-
2007
- 2007-12-14 CN CNA2007800478825A patent/CN101600459A/zh active Pending
- 2007-12-14 MX MX2009006547A patent/MX2009006547A/es unknown
- 2007-12-14 KR KR1020097015486A patent/KR20090094163A/ko not_active Withdrawn
- 2007-12-14 WO PCT/US2007/087524 patent/WO2008079732A2/en not_active Ceased
- 2007-12-14 AU AU2007337101A patent/AU2007337101A1/en not_active Abandoned
- 2007-12-14 BR BRPI0720738-7A patent/BRPI0720738A2/pt not_active Application Discontinuation
- 2007-12-14 CA CA002673543A patent/CA2673543A1/en not_active Abandoned
- 2007-12-14 EP EP07865672A patent/EP2099494A2/en not_active Withdrawn
- 2007-12-14 RU RU2009123024/15A patent/RU2009123024A/ru not_active Application Discontinuation
- 2007-12-14 JP JP2009543096A patent/JP2010513559A/ja active Pending
- 2007-12-21 CL CL2007003780A patent/CL2007003780A1/es unknown
-
2009
- 2009-06-19 ZA ZA200904331A patent/ZA200904331B/xx unknown
-
2011
- 2011-04-26 US US13/093,976 patent/US20110201791A1/en not_active Abandoned
-
2015
- 2015-04-24 US US14/695,582 patent/US9981045B2/en not_active Expired - Lifetime
-
2018
- 2018-05-07 US US15/972,758 patent/US11969474B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010513559A (ja) | 2010-04-30 |
| US20070184071A1 (en) | 2007-08-09 |
| CN101600459A (zh) | 2009-12-09 |
| US7955605B2 (en) | 2011-06-07 |
| WO2008079732A3 (en) | 2008-12-24 |
| US20150231270A1 (en) | 2015-08-20 |
| US20180256739A1 (en) | 2018-09-13 |
| US11969474B2 (en) | 2024-04-30 |
| CA2673543A1 (en) | 2008-07-03 |
| US20110201791A1 (en) | 2011-08-18 |
| WO2008079732A2 (en) | 2008-07-03 |
| EP2099494A2 (en) | 2009-09-16 |
| RU2009123024A (ru) | 2011-01-27 |
| MX2009006547A (es) | 2009-06-26 |
| US9981045B2 (en) | 2018-05-29 |
| AU2007337101A1 (en) | 2008-07-03 |
| KR20090094163A (ko) | 2009-09-03 |
| CL2007003780A1 (es) | 2009-01-23 |
| BRPI0720738A2 (pt) | 2014-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282638A (en) | A multivalent pneumomuroral protein-polysaccharide conjugate preparation | |
| ZA200904331B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| ZA200904619B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| HRP20190037T1 (hr) | Cjepivo na bazi konjugata pneumokoknih polisaharida | |
| HUS2100013I1 (hu) | Diftéria-toxin-interleukin-3 konjugátumokon alapuló eljárások és készítmények | |
| IL227934A0 (en) | Immunogenic preparation | |
| PT1968630T (pt) | Composições imunogénicas de pcv2 multivalentes | |
| ZA200807961B (en) | Methods for preparing complex multivalent immunogenic conjugates | |
| AP2010005173A0 (en) | Compositions comprising pneumococcal antigens | |
| ZA200902540B (en) | Immunization protocol against the 4 dengue serotypes | |
| HRP20151122T1 (hr) | Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae | |
| EP1963522A4 (en) | MULTIVALENT MENINGOCOCCAL DERIVATIVE POLYSACCHARIDE-PROTEIN CONJUGATES AND VACCINE | |
| GB0606416D0 (en) | Immunogenic composition | |
| ZA200805347B (en) | Pneumococcal polysaccharide conjugate vaccine | |
| GB0606417D0 (en) | Immunogenic composition | |
| SG10201403055VA (en) | Conjugation methods | |
| AU2007203489A1 (en) | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |